Navigation Links
bioRASI Completes Acquisition of Ukrainian CRO
Date:3/28/2013

Aventura, FL (PRWEB) March 28, 2013

bioRASI, a full service, global Contract Research Organization (CRO), announced today that it has acquired Sponsors Clinical Research Group, LLC (SCRG), a Ukrainian based regulatory and clinical CRO. SCRG was established in 2004 and has been conducting clinical studies in an extensive range of therapeutic areas including cardiology, neurology, oncology, endocrinology and pulmonology.

“We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure,” explained Dr. Boris Reznik, Chairman of bioRASI. “This acquisition enhances bioRASI’s global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs.”

The acquisition of SCRG addresses the ever-increasing demand for optimizing global clinical trials and builds upon bioRASI’s already commanding presence throughout Eastern Europe.

“While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI,” explained Dr. Veklych, SCRG’s Executive Director. “An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI’s winning team.”    

About bioRASI
bioRASI is an award-winning Full Service Global CRO providing clinical development services that optimize its sponsors’ scientific, clinical, and business results. bioRASI facilitates obtaining global marketing approval for drugs, biotherapeutics, and medical devices by delivering high quality regulatory and clinical strategies, solutions and services. The Company's unique access to the largest facilities and patient populations worldwide saves clients critical time. bioRASI's services include program optimization, project management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI is headquartered in Aventura, FL and has regional offices and operations across North America and around the world.

Click here for a copy of our White Paper Series.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10578507.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Novira Therapeutics Completes $25 Million Series A Financing
2. BGI-Shenzhen Completes Acquisition of Complete Genomics
3. Amarantus Completes Name Change and CUSIP Change
4. Advanced Cell Diagnostics Completes $12 Million Series B Financing
5. Synthetic Biologics Completes $10.8 Million Private Placement Financing
6. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
7. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
8. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
9. China Integrated Energy Inc. Completes Independent Investigation
10. Oxford Finance Completes $271.4 Million Securitization Transaction
11. inVentiv Health Completes Acquisition of Kforce Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017  Former NFL players who had ... functions later in life, according to a preliminary study released ... Neurology,s 69th Annual Meeting in Boston , ... are complex movements where the muscles and nerves work together, ... ...
(Date:2/18/2017)... Arlington Heights, IL (PRWEB) , ... February 17, ... ... Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood ... Gaylord Palms Convention Center in Orlando, Fla. , The combined scientific ...
(Date:2/17/2017)... , Feb. 17, 2017  If only one ... had a mutation-conferring resistance to chemotherapy, thousands of ... research has focused on finding these mutations in ... from circulating tumor DNA in blood — to ... therapeutics. Unfortunately, however, detecting these genetic ...
(Date:2/16/2017)... , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an ... to find a better treatment for triple negative breast cancer ... France program. The YEi ... accelerator designed to help entrepreneurs grow their business in ... of eight American companies selected to complete an intensive one ...
Breaking Biology Technology:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):